ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea · Delayed Price · Currency is KRW 5,960.00
-20.00 (-0.33%)
Last updated: Sep 16, 2025, 2:50 PM KST
ImmuneOncia Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Operating Revenue | 765.75 | 654.54 | 110 | 7,733 | 35.95 | 2.5 | Upgrade |
Other Revenue | - | - | - | - | 0 | - | Upgrade |
| 765.75 | 654.54 | 110 | 7,733 | 35.95 | 2.5 | Upgrade | |
Revenue Growth (YoY) | -90.10% | 495.04% | -98.58% | 21413.29% | 1337.90% | 66.67% | Upgrade |
Cost of Revenue | 11.43 | 11.12 | 17.09 | 17.85 | 7.8 | 5.36 | Upgrade |
Gross Profit | 754.31 | 643.42 | 92.91 | 7,716 | 28.15 | -2.86 | Upgrade |
Selling, General & Admin | 7,898 | 4,964 | 5,038 | 7,662 | 5,075 | 2,958 | Upgrade |
Research & Development | 4,858 | 7,386 | 6,034 | 14,243 | 6,012 | 8,914 | Upgrade |
Other Operating Expenses | 37.86 | 19.64 | 19.55 | 15.15 | 12.63 | 3.3 | Upgrade |
Operating Expenses | 13,666 | 13,242 | 11,890 | 22,789 | 11,924 | 12,638 | Upgrade |
Operating Income | -12,911 | -12,599 | -11,797 | -15,073 | -11,896 | -12,641 | Upgrade |
Interest Expense | -3.9 | -6.93 | -3.13 | - | - | - | Upgrade |
Interest & Investment Income | 526.39 | 690.31 | 769.15 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 4.1 | -49.41 | 9.51 | 75.7 | 192.43 | 21.03 | Upgrade |
Other Non Operating Income (Expenses) | 6,229 | 6,278 | 19,886 | 11,507 | -48,783 | -6,528 | Upgrade |
EBT Excluding Unusual Items | -6,155 | -5,686 | 8,865 | -3,490 | -60,487 | -19,148 | Upgrade |
Gain (Loss) on Sale of Assets | -0.55 | -0.55 | -0.77 | -1.38 | -3.18 | -9.39 | Upgrade |
Pretax Income | -6,156 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade |
Net Income | -6,156 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade |
Net Income to Common | -6,156 | -5,687 | 8,864 | -3,492 | -60,490 | -19,158 | Upgrade |
Shares Outstanding (Basic) | 63 | 56 | 52 | 52 | 46 | 5 | Upgrade |
Shares Outstanding (Diluted) | 63 | 56 | 52 | 52 | 46 | 5 | Upgrade |
Shares Change (YoY) | 20.04% | 7.35% | 0.64% | 12.17% | 904.47% | -0.01% | Upgrade |
EPS (Basic) | -98.40 | -101.00 | 169.00 | -67.00 | -1302.00 | -4142.00 | Upgrade |
EPS (Diluted) | -98.40 | -101.00 | 169.00 | -67.00 | -1302.00 | -4142.00 | Upgrade |
Free Cash Flow | -18,349 | -14,750 | -8,766 | -15,337 | -2,078 | -10,322 | Upgrade |
Free Cash Flow Per Share | -293.31 | -261.96 | -167.13 | -294.29 | -44.72 | -2231.70 | Upgrade |
Gross Margin | 98.51% | 98.30% | 84.47% | 99.77% | 78.31% | -114.52% | Upgrade |
Operating Margin | -1686.12% | -1924.80% | -10724.51% | -194.91% | -33093.66% | -505642.37% | Upgrade |
Profit Margin | -803.92% | -868.86% | 8058.20% | -45.15% | -168272.99% | -766313.44% | Upgrade |
Free Cash Flow Margin | -2396.20% | -2253.53% | -7968.93% | -198.32% | -5779.96% | -412888.34% | Upgrade |
EBITDA | -11,948 | -11,547 | -10,766 | -13,992 | -10,870 | -11,684 | Upgrade |
EBITDA Margin | - | - | - | -180.93% | - | - | Upgrade |
D&A For EBITDA | 963.38 | 1,051 | 1,031 | 1,081 | 1,026 | 956.83 | Upgrade |
EBIT | -12,911 | -12,599 | -11,797 | -15,073 | -11,896 | -12,641 | Upgrade |
EBIT Margin | - | - | - | -194.91% | - | - | Upgrade |
Advertising Expenses | - | 1 | 1 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.